However, newer classes of medications—such as sodium-glucose cotransporter 2 inhibitors (SGLT2i) and GLP-1 receptor agonists—have been shown to reduce the risk of CV events in patients with T2DM and established ASCVD [19–21]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.